The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Open accessAbstract
Purpose: To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid leukemia unsuitable for intensive chemotherapy. Patients and Methods: In this trial, patients at least 61 years old were centrally randomized (1:1) to receive either a single induction course of GO (6 mg/m 2 on day 1 and 3 mg/m 2 on day 8) or BSC. Patients who did not progress after GO induction could receive up to eight monthly infusions of the immunoconjugate at 2 mg/m 2 . Randomization was stratified by age, WHO performance score, CD33 expression status, and center. The primary end point was overall survival (OS) by intention-to-treat analysis. Results: A total of 237 patients were randomly assigned (118 to GO and 119 to BSC). The median OS was 4.9 months (95% CI, 4.2 to 6.8 months) in the GO group and 3.6 months (95% CI, 2.6 to 4.2 months) in the BSC group (hazard ratio, 0.69; 95% CI, 0.53 to 0.90; P = .005); the 1-year OS rate was 24.3% with GO and 9.7% with BSC. The OS benefit with GO was consistent across most subgroups, and was especially apparent in patients with high CD33 expression status, in those with favorable/intermediate cytogenetic risk profile, and in women. Overall, complete remission (CR [complete remission] + CRi [CR with incomplete recovery of peripheral blood counts]) occurred in 30 of 111 (27%) GO recipients. The rates of serious adverse events (AEs) were similar in the two groups, and no excess mortality from AEs was observed with GO. Conclusion: First-line monotherapy with low-dose GO, as compared with BSC, significantly improved OS in older patients with acute myeloid leukemia who were ineligible for intensive chemotherapy. No unexpected AEs were identified and toxicity was manageable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Self-citationCastaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464
Survival for older patients with acute myeloid leukemia: a population-based study
Oran, B., & Weisdorf, D. J. (2012) · Haematologica · doi:10.3324/haematol.2012.066100 · Cited by 423
Döhner, H., Lübbert, M., Fiedler, W., Fouillard, L., Haaland, A., Brandwein, J. M., Lepretre, S., Reman, O., Turlure, P., Ottmann, O. G., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560557 · Cited by 231
Burnett, A. K., Hills, R. K., Hunter, A. E., Milligan, D., Kell, W. J., Wheatley, K., Yin, J., McMullin, M. F., Dignum, H., Bowen, D., et al. (2013) · Leukemia · doi:10.1038/leu.2012.229 · Cited by 161
Walter, R. B., Raden, B. W., Kamikura, D. M., Cooper, J. A., & Bernstein, I. D. (2004) · Blood · doi:10.1182/blood-2004-07-2784 · Cited by 155
Acute myeloid leukaemia in the elderly: a review
Pollyea, D. A., Kohrt, H. E. K., & Medeiros, B. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08470.x · Cited by 150
Estey, E. H., Thall, P. F., Giles, F. J., Wang, X., Cortes, J. E., Beran, M., Pierce, S. A., Thomas, D. A., & Kantarjian, H. M. (2002) · Blood · doi:10.1182/blood.v99.12.4343 · Cited by 138
Burnett, A. K., Russell, N. H., Hunter, A., Milligan, D. W., Knapper, S., Wheatley, K., Yin, J., McMullin, M. F., Ali, S., Bowen, D., et al. (2013) · Blood · doi:10.1182/blood-2013-04-496596 · Cited by 132
Azacitidine for the treatment of patients with acute myeloid leukemia
Maurillo, L., Venditti, A., Spagnoli, A., Gaïdano, G., Ferrero, D., Olíva, E. N., Lunghi, M., D’Arco, A. M., Levis, A., Pastore, D., et al. (2011) · Cancer · doi:10.1002/cncr.26354 · Cited by 128
Self-citationGemtuzumab Ozogamicin: Time to Resurrect?
Ravandi, F., Estey, E. H., Appelbaum, F. R., Lo‐Coco, F., Schiffer, C. A., Larson, R. A., Burnett, A. K., & Kantarjian, H. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0132 · Cited by 104
Treatment of acute myeloid leukemia: are we making progress?
Burnett, A. K. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.1.3797038 · Cited by 95
Management of older or unfit patients with acute myeloid leukemia
Walter, R. B., & Estey, E. H. (2014) · Leukemia · doi:10.1038/leu.2014.216 · Cited by 92
Nabhan, C., Rundhaugen, L. M., Riley, M. B., RADEMAKER, A. W., Boehlke, L., Jatoi, M., & Tallman, M. S. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.04.011 · Cited by 75
Amadori, S., Suciu, S., Selleslag, D., Stasi, R., Alimena, G., Baila, L., Rizzoli, V., Borlenghi, E., Gaïdano, G., Magro, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08095.x · Cited by 58
Self-citationBurnett, A. K., Russell, N. H., Culligan, D. J., Cavanagh, J. D., Kell, J., Wheatley, K., Virchis, A., Hills, R. K., & Milligan, D. W. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09165.x · Cited by 56
Dennis, M., Russell, N. H., Hills, R. K., Hemmaway, C. J., Panoskaltsis, N., McMullin, M., Kjeldsen, L., Dignum, H., Thomas, I., Clark, R. E., et al. (2015) · Blood · doi:10.1182/blood-2014-10-608117 · Cited by 48
Burnett, A. K., Hills, R. K., Hunter, A., Milligan, D. W., Kell, J., Wheatley, K., Yin, J. A. L., Mcmullin, M., Cahalin, P. A., Craig, J. I. O., et al. (2011) · Leukemia · doi:10.1038/leu.2011.59 · Cited by 40
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
De Kouchkovsky, I., & Abdul-Hay, M. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.50 · Cited by 1,317
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Metadata
- Authors
- Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., Magro, D., De Fabritiis, P., Muus, P., Alimena, G., Mancini, M., Hagemeijer, A., Paoloni, F., Vignetti, M., Fazi, P., Meert, L., Ramadan, S. M., Willemze, R., de Witte, T., & Baron, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-03-20
- Volume
- 34
- Issue
- 9
- Pages
- 972-979
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2259204994
- Cited by
- 362
- References
- 29
- FWCI
- 29.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.